The present disclosure relates generally to a head located implantable neurostimulation system and, specifically, to methods of implanting a fully head located cranial and peripheral neurostimulator system that is utilized for the purpose of treating chronic head pain.
Neurostimulation systems comprising implantable neurostimulation leads are used to treat chronic pain. Conventional implantable peripheral neurostimulation leads are designed for placement in the spinal canal as part of a spinal cord stimulation system, and for the therapeutic purpose of treating various forms of chronic back and extremity pain.
Until the present invention, implantable neurostimulator systems for head pain essentially involved deep brain stimulators, where leads were positioned in the substance of the brain itself; traditional spinal cord stimulator systems that were adopted and adapted for the treatment of head pain; or implantable systems for neurostimulation of the vagus nerve or sphenopalatine ganglion.
Historically, the most common case involves the adaption of spinal cord stimulators for the purpose of peripheral nerve stimulation, such that all publicly available implantable neurostimulation systems utilized for the treatment of chronic head pain have been originally designed specifically as spinal cord stimulator systems for the therapeutic purpose of treating chronic back and extremity pain. As these systems were developed for implantation in the back, their design did not contemplate the anatomic and physiologic features unique to the head and chronic head pain, which are so significantly different from the anatomy of the spinal canal, and pathophysiology of chronic back pain, that when spinal cord stimulators were utilized for cranial implants, the clinical problems associated with these differences ultimately manifested themselves.
These well-documented and clinically significant problems relate to issues of patient safety and satisfaction, including the risk of an inadequate, or suboptimal, therapeutic response; issues with patient comfort and cosmetics; and an increased risk of surgical complications and technical problems. Several specific inherent deficiencies in device design and method of implant underlie these deficiencies and problems. Likely the most common methodological deficiency is the fact that the implantable pulse generator (IPG) must necessarily be implanted at a considerable anatomic distance for the cranial lead implants. Indeed, the leads must pass from their distal cranial implant positions across the cervical region and upper back to the IPG implant location, which are most commonly in the lower back, lower abdomen, or gluteal region. The related problems are due the fact that the leads must cross multiple anatomic motion segments (neck and back). Here, the simple motions of normal daily life produce adverse tension and torque forces on the leads across these motion segments, which in turn increase the risk of technical problems, including lead migration and/or lead fracture. A second problem relates to the relatively large size of the IPG, which contributes to local discomfort, cosmetic concerns, and the fact that should the IPG pocket become infected, the related clinical problem parallels the relatively large size of the IPG; that is, the larger the IPG, the larger the pocket, and the larger and more problematic any complicating infection. Additional inherent problems include the added risks, especially infection, wound dehiscence, discomfort, and cosmetic problems associated with the multiple additional incisions that are necessary to pass the leads from the IPG to their terminal positions in the head.
In various implementations, an implantable head-located, unibody peripheral nerve stimulation system may be configured for implantation of substantially all electronics, including an on-site battery, at or near the implanted electrodes on the skull. The system may include an implantable pulse generator (IPG) from which two neurostimulating leads may extend to a length sufficient to provide therapeutic neurostimulation unilaterally over the frontal, parietal and occipital regions of the hemicranium. The system may be operable to provide medically acceptable therapeutic neurostimulation to multiple regions of the head, including the frontal, parietal and occipital regions of the hemicranium, substantially simultaneously.
Each of the leads may include an extended lead body; a plurality of surface metal electrodes disposed along the lead body, which may be divided into two or more electrode arrays; and a plurality of internal electrically conducting metal wires running along at least a portion of the length of the lead body and individually connecting an internal circuit of the IPG to individual surface metal electrodes. The extended lead body may comprise a medical grade plastic. The IPG may include a rechargeable battery, an antenna coil, and an application specific integrated circuit (ASIC). The IPG may be configured for functionally connecting with an external radiofrequency unit. The external radiofrequency unit may be operable to perform various functions including recharging the rechargeable battery, diagnostically evaluating the IPG, and programming the IPG.
Implementations may include one or more of the following features. The IPG may be of proper aspect ratio with respect to the specific site of intended implantation in the head, such as an area posterior to and/or superior to the ear. There may be an external portable programming unit that is capable of achieving a radiofrequency couple to the implanted IPG. The IPG may have a rechargeable battery as a power source. The rechargeable battery may be inductively recharged through the skin.
Implementations may include one or more of the following features. A neurostimulating lead may not include a central channel for a stylet. A neurostimulating lead may have a smaller diameter than conventional leads.
Implementations may include one or more of the following features. The system may include the disposition of a sufficient plurality of surface electrodes over a sufficient linear distance along the neurostimulating leads to enable medically adequate therapeutic stimulation across multiple regions of the head, including the frontal, parietal, and occipital region of the hemicranium substantially simultaneously. The extended array of surface electrodes may be divided into two or more discrete terminal surface electrode arrays. The linear layout of the multiple surface electrode arrays may include at least one array positioned over the frontal region, at least one array positioned over the parietal region, and at least one array positioned over the occipital region.
Specific intra-array design features may include variations in the specific number of electrodes allotted to each group; the shape of the electrodes, e.g., whether the electrodes are cylindrical or flattened; the width of each electrode within each array, and the linear distance intervals of separation of the electrodes within each array.
Various implementations may include a plurality of connection ports that can be connected with a plurality of leads and thus allow for attaching additional leads.
In various implementations, methods of treating chronic pain may include methods of treating chronic head and/or face pain of multiple etiologies, including migraine headaches; and other primary headaches, including cluster headaches, hemicrania continua headaches, tension type headaches, chronic daily headaches; further including secondary headaches, such as cervicogenic headaches and other secondary musculoskeletal headaches.
In various implementations, methods of treating chronic pain may include methods of treating head and/or face pain of multiple etiologies, including neuropathic head and/or face pain, nociceptive head and/or face pain, and/or sympathetic related head and/or face pain.
In various implementations, methods of treating chronic pain may include methods of treating head and/or face pain of multiple etiologies, including greater occipital neuralgia, as well as the other various occipital neuralgias, supraorbital neuralgia, auriculo-temporal neuralgia, infraorbital neuralgia, and other trigeminal neuralgias, and other head and face neuralgias.
In various implementations the unibody neurostimulation system with two leads, including one with multiple arrays, is fully implanted with all components positioned within the subcutaneous layer of the skin and without the requirement of sutures, anchors, or other fixation devices to fix the systems, or portions thereof in position.
In one embodiment, a low profile implantable pulse generator includes a battery, a printed circuit board and a generally rectangular metal can enclosing the printed circuit board and the battery. The can includes a top piece having a top side with a recessed portion having an interior side wall and an open side at a first end of the can with a plurality of cut-outs formed in the recessed portion and a coil positioned adjacent the first end of the metal can, the coil operable to charge the battery. A plurality of leads, each including a plurality of wires, extend from the first end of the can proximate to and across the coil. The wires extend though the open side of the recessed portion below the plane defined by top side of the can with a plurality of the wires transmitting low frequency pulses from the printed circuit board to a selected frontal, parietal, or occipital nerve region. The coil may have a substantially linear first side proximate the first end of the can with a substantially semicircular second side extending away from the first end of the can. The substantially linear first side of the coil may extend substantially parallel to the edge of the first side of the can. The leads may extend from the first end of the can proximate to and across the substantially linear first side of the coil and proximate to and across the semicircular second side of the coil.
In one variation, the low profile implantable pulse generator may include a feedthrough positioned over each of the cutouts, the feedthrough comprising a substantially flat metal plate portion with a plurality of ceramic rings extending through the flat metal plate portion. Each of the ceramic rings has a conductive pin extending through the ring substantially perpendicular to the flat metal plate portion. A first one of the feedthroughs may connect the coil to the printed circuit board and second ones of the feedthroughs connect the wires in the leads to the printed circuit board. The first feedthrough and the second feedthroughs may be positioned at the first end of the can with the first feedthrough proximate one of the second feedthroughs. The wires may be connected to the pins to extend substantially perpendicular to the pins below the plane defined by top side of the can.
In one embodiment, the pulse generator is encapsulated in silicone with the silicone forming a center portion encapsulating the can and angled lobes at each end of the can wherein the coil is encapsulated in one of the lobes at the first end of the center section. The lobes may be angled downward from about 10 to about 20 degrees from the center section.
The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the implementations will be apparent from the description and drawings.
For a more complete understanding of this disclosure and its features, reference is now made to the following description, taken in conjunction with the accompanying drawings, in which:
Referring now to the drawings, wherein like reference numbers are used herein to designate like elements throughout, the various views and embodiments of implantable head located neurostimulation system for head pain are illustrated and described, and other possible embodiments are described. The figures are not necessarily drawn to scale, and in some instances the drawings have been exaggerated and/or simplified in places for illustrative purposes only. One of ordinary skill in the art will appreciate the many possible applications and variations based on the following examples of possible embodiments.
The present disclosure provides a fully head located implantable peripheral neurostimulation system designed for the treatment of chronic head pain. It incorporates multiple elements and features that take into account the unique anatomic, physiologic, and other related challenges of treating head pain with implantable neurostimulation, thereby greatly improving on therapeutic response, patient safety, medical risk, and medical costs, which combine to improve overall patient satisfaction.
Prior implantable peripheral neurostimulation systems and components, including leads and pulse generators, have been designed and developed specifically as spinal cord stimulator systems and for the specific therapeutic purpose of treating chronic back and extremity pain. Over the years, these spinal cord stimulators were ultimately adopted and adapted for use as implantable peripheral nerve stimulators for the treatment of migraine headaches, and other forms of chronic head pain; however, they were so utilized with full recognition of the inherent risks and limitations given that they were developed only to address, and accommodate to, the unique anatomic and physiologic features of the back and chronic back pain.
U.S. Provisional Patent Application Ser. No. 61/865,893 describes the manifold problems associated with the application of spinal cord stimulators for head pain as fundamentally due to design flaws associated with, and inherent to, the use of an implantable therapeutic device in an area of the body that it was not designed for.
Indeed, the anatomy of the head, and the pathophysiology of headaches, and other forms of head pain, are so significantly different from the anatomy of the spinal canal, and pathophysiology of chronic back pain, that when spinal cord stimulators are utilized for cranial implants, the clinical problems associated with these differences manifest themselves. Importantly, these well-documented problems are clinically very significant and include issues of patient safety and satisfaction, the risk of an inadequate, or suboptimal, therapeutic response; and issues with patient comfort and cosmetics; as well as a recognized increased risk of surgical complications and technical problems.
These medical issues stem from the design of conventional leads and the IPG. Conventional lead designs include a relatively large diameter, a cylindrical shape, (often) inadequate length and the necessity of implanting the IPG in the torso and distant from the distal leads, and a number and disposition of the surface electrodes and active lead arrays that do not match the requirements. A cylindrical lead of relatively large diameter results in increased pressure on, and manifest tenting of, the overlying skin, particularly of the forehead. Because conventional leads are of inadequate length to extend from the head to the IPG implant site, commonly in the lower back, abdomen, or gluteal region, lead extensions are often employed, and there are attendant risks of infection, local discomfort, and cosmetic concerns.
With respect to prior leads: 1) There is only a single array of electrodes, with common lead options including 4, 8, or 16 electrodes disposed over that single array; 2) The array is relatively short with most leads having an array of from 5-12 cm in length: 3) Within this single array, the individual electrodes are disposed uniformly with constant, equal inter-electrode distances. This results in the need to implant multiple (often four or more) of the conventional leads to adequately cover the painful regions of the head.
There are several practical clinical outcomes that result from the use of prior leads for the treatment of chronic head pain. First, since they comprise a single, relatively short active array, the currently available leads provide therapeutic stimulation to only a single region of the head; that is, they can provide stimulation to only the frontal region, or a portion of the parietal region, or a portion of the occipital region. Therefore, if a patient has pain that extends over multiple regions, then multiple separate lead implants are required—basically one lead implant is required for each unilateral region. A great majority of patients with chronic headaches experience holocephalic pain; that is they experience pain over the frontal and parietal and occipital regions bilaterally. Therefore, commonly these patients will need 4 to 7 leads implanted to achieve adequate therapeutic results (2 or 3 leads on each side).
Second, the need for multiple leads includes considerable added expense, and more importantly, added medical risk associated with adverse events attendant to the multiple surgical procedures. Such adverse events include an increased risk of infection, bleeding, and technical issues with the leads, e.g., lead fracture, lead migration, and local irritation.
Third, as the clinical database discloses, the inter-electrode spacing may be of central therapeutic significance. That is, for example, whereas commonly pain over the occipital region is consistently effectively treated by quadripolar leads (leads with four evenly spaced electrodes) that have the electrodes relatively widely spaced apart (approximately a cm or more apart), clinically it is often found that electrodes configurations that are more narrowly spaced may be more effective over the supraorbital nerve and regions. Thus, a quadripolar lead that has the electrodes only 1-2 mm apart may be more effective in this region, as it allows for more precise control of the delivered electrical pulse wave delivery.
Inter-electrode spacing is also of therapeutic significance. For example, whereas pain over the occipital region is commonly treated effectively by systems incorporating relatively widely-spaced quadripolar leads (four electrodes at approximately 1 cm or more intervals), more narrowly spaced contacts are often more effective over the supraorbital region.
When an IPG implant designed for spinal cord stimulation systems is employed as a peripheral nerve stimulator for head pain, several outcomes result. First, the IPG is implanted at a considerable anatomic distance for the cranial lead implants. Indeed, the leads must pass from their distal cranial implant positions across the cervical region and upper back to the IPG implant location, which are most commonly in the lower back, lower abdomen, or gluteal region. The leads must cross multiple anatomic motion segments, including the neck and upper back and/or chest at a minimum, and commonly include the mid back, lower back and waist segments, as well. The simple motions of normal daily life produce adverse tension and torque forces on the leads across these motion segments, which in turn increases the risk of various outcomes, including lead migration and/or lead fracture. In addition, the relatively large size of a spinal cord stimulator IPG contributes to local discomfort, cosmetic concerns, and increased risk of infection that may become larger and harder to treat in proportion to the size of the IPG pocket.
The present disclosure is directed to an implantable head-located unibody peripheral neurostimulation system that includes an IPG from which two neurostimulating leads extend to a length sufficient to allow for therapeutic neurostimulation unilaterally over the frontal, parietal and occipital regions of the head.
The present disclosure addresses and effectively solves problems attendant to publicly available leads. The most important of these is the fact that current leads can only adequately stimulate a single region of the head due to design element flaws associated with terminal surface electrode number and disposition. The disclosure additionally addresses and solves other problems inherent with the currently available leads, including problems with cosmetics and patient comfort, particularly over the frontal regions, due the uncomfortable pressure placed on the skin of the forehead, due the cylindrical shape and relatively large diameter of the distal portion of the lead. Finally, the lead of the present disclosure solves the currently available leads' problem of inadequate lead length to reach a gluteal location of the implantable pulse generator, which therefore necessitates the additional risk and expense of further surgery to implant lead extensions.
In one aspect, the implantable, head-located, neurostimulation system for head pain is operable for subcutaneous implantation in the head, and to provide neurostimulation therapy for chronic head pain, including chronic head pain caused by migraine and other headaches, as well as chronic head pain due other etiologies. The peripheral neurostimulator system disclosed herein takes into account unique anatomic features of the human head, as well as the unique, or singular, features of the various pathologies that give rise to head pain, including migraine and other headaches, as well as other forms of chronic head pain. This lead design for implantation in the head for chronic head pain recognizes that thus far all commercially available systems that have been clinically utilized for implantation as a peripheral neurostimulator system were actually originally designed specifically for placement in the epidural space, as part of a spinal cord stimulation system, for the therapeutic purpose of treating chronic back and/or extremity pain. Thus, there are currently no commercially available leads or full systems that have designs in the public domain, which have been designed and developed for use in the head and for head pain.
In another aspect, the implantable, head-located, neurostimulation system for head pain comprises multiple design features, including disposition of a sufficient plurality of surface electrodes over a sufficient linear distance along the distal lead, such as will result in a lead that, as a single lead, is capable of providing medically adequate therapeutic stimulation over the entire hemicranium; that is, over the frontal, parietal, and occipital region substantially simultaneously. Currently available systems, which were designed specifically for epidural placement for chronic back pain, are capable of only providing stimulation over a single region; that is over either the frontal region alone, or the parietal region alone, or the occipital region alone.
Currently available leads, which were designed specifically for epidural placement for chronic back pain, are capable of only providing stimulation over a single region; that is over either the frontal region alone, or the parietal region alone, or the occipital region alone.
In yet another aspect, the implantable, head-located, neurostimulation system for head pain comprises multiple design features, including the physical grouping of the extended array of surface electrodes into three or more discrete terminal surface electrode arrays. The linear layout of these two or more (preferably three or more) surface electrodes arrays is designed such that following implantation there would be at least one array positioned over the frontal region, at least one array positioned over the parietal region, and at least one array positioned over the occipital region. This feature further improves upon therapeutic effectiveness of the extended terminal surface electrode array sufficient for hemicranial stimulation by allowing for more precise control of the therapeutic neurostimulation parameters.
In still another aspect, the implantable, head-located, neurostimulation system for head pain comprises multiple design features, including incorporating individual design features within each of the three or more individual surface electrode arrays; examples of such intra-array design features would include the specific number of electrodes allotted to each group; whether the electrodes are cylindrical or flattened; the width of each electrode within each array, and the linear distance intervals of separation of the electrodes within each array. This feature further improves upon therapeutic effectiveness of the extended terminal surface electrode array sufficient for hemicranial stimulation, and the grouping of these electrodes into three or more separate surface electrode arrays, by providing each specific array location with a unique intra-array design that takes into account, and thereby seeks to optimize, design elements that are known to be possibly or likely beneficial to the therapeutic end result, given the anticipated post-implant anatomic location of that array.
In yet another aspect, the implantable, head-located, neurostimulation system for head pain comprises multiple design features, including incorporating individual design features into a single lead design and thereby achieving additive benefits.
In still another aspect, an implantable, head-located, neurostimulation system for head pain results in a marked decrease in the number of separate lead implants required to adequately treat a single patient. A single implant will provide the same therapeutic anatomic coverage that it would take the implantation of three or four of the currently available leads; that is, instead of the current implant, which often calls for three or more leads to be implanted to provide adequate hemicranial coverage, the same anatomic region may be covered with a single stimulator lead implant. The lead can provide extended coverage over the full hemicranium; that is achieving medically acceptable neurostimulation unilaterally over the frontal, parietal, and occipital regions simultaneously. In contrast, publicly known leads are able to consistently provide medically acceptable neurostimulation therapy only over a single region; meaning that it would require three separate surgically placed lead implants to achieve the same therapeutic coverage of a single implant of a lead of the present disclosure. This will decrease the total number of surgeries required, as well as the extent of each individual surgery, for many patients.
In another aspect, the present disclosure is directed to a system that is fully localized to the head, which obviates the requirement of currently available systems of having long leads and extensions extending across the neck and back to IPG locations commonly in the low back and gluteal region, and thereby decreases the risk of problems attendant to such long leads and extensions, including discomfort, infection, technical extension issues such as fracture, and other morbidities. This ultimately results in a decreased number of surgeries required by a patient.
In other aspects the system may include one or more of the following features. A neurostimulating lead may not require a central channel for a stylet, which would be necessary to secure the lead against migration. A neurostimulating lead may have a smaller diameter than currently available leads.
In other aspects the system may include one or more of the following features. The system may include the disposition of a sufficient plurality of surface electrodes over a sufficient linear distance along the system's leads to enable medically adequate therapeutic stimulation across multiple regions of the head, and preferably the entire hemicranium: that is, over the frontal, parietal, and occipital region simultaneously. The extended array of surface electrodes may be divided into two or more discrete terminal surface electrode arrays, each capable of being designed for the particular associated region to be stimulated. The preferred linear layout of these multiple surface electrode arrays includes at least one array positioned over the frontal region, at least one array positioned over the parietal region, and at least one array positioned over the occipital region.
In other aspects, intra-array design features may include variations in the specific number of electrodes allotted to each group: the shape of the electrodes, e.g., whether the electrodes are cylindrical or flattened; the width of each electrode within each array, and the linear distance intervals of separation of the electrodes within each array.
In other aspects, the system may include a plurality of connection ports that can be connected with a plurality of leads and thus allow for attaching additional leads should they later be required.
In another aspect, an implantable, head-located, neurostimulation system for head pain comprises multiple design features; including features aimed at improving patient safety by improving the incidence of adverse events, including the risk of infection, as well as the risk and incidence of known technical problems associated with implanted leads, including lead migration and lead fracture, amongst others. The lead may comprise two or more (i.e. three or more) surface electrode arrays, each uniquely designed, that are disposed over a sufficient lead length to allow for medically acceptable therapeutic neurostimulator coverage of at least regions within the supraorbital, parietal, and occipital cranial regions. To achieve the same clinical coverage from a prior art implant, it would require three or more separately surgically implanted leads that are first implanted, followed by waking the patient up and activating the electrodes to determine if they are properly placed and, once the surgeon is satisfied, the leads are connected to an IPG and the IPG disposed in a pocket somewhere in the body, typically in the lower torso. Therefore, by reducing the number of surgical incisions, as well as the number of surgically implanted leads, the associated risks of adverse events are proportionally diminished.
In yet another aspect, an implantable, head-located, neurostimulation system for head pain may treat chronic head and/or face pain of multiple etiologies, including migraine headaches; and other primary headaches, including cluster headaches, hemicrania continua headaches, tension type headaches, chronic daily headaches, transformed migraine headaches; further including secondary headaches, such as cervicogenic headaches and other secondary musculoskeletal headaches; including neuropathic head and/or face pain, nociceptive head and/or face pain, and/or sympathetic related head and/or face pain; including greater occipital neuralgia, as well as the other various occipital neuralgias, supraorbital neuralgia, auriculotemporal neuralgia, infraorbital neuralgia, and other trigeminal neuralgias, and other head and face neuralgias.
In other aspects, an implantable, head-located, neurostimulation system for head pain may not require a central channel for stylet placement over its distal (frontal) portions. The lead may improve patient comfort and cosmetics by virtue of its relatively small diameter over the distal portions of the lead, partially due the lack of a central stylet channel, as well as due to a progressive decrease in the number of internal wires continuing after each terminal electrode. The lead may further improve cosmetic appearance and patient comfort by incorporating a flattened lead design for that portion of the lead expected to be over the frontal portion of the head. The lead may be compatible with currently available implantable pulse generators. The lead may incorporate an electrode array design that is capable as a single lead of providing medically acceptable neurostimulation coverage over the supraorbital, auriculotemporal, and occipital nerves unilaterally. The lead may be of sufficient length to adequately reach all common pulse generator locations, thereby potentially obviating the need for lead extensions and in turn decreasing the risk of problems attendant to such extensions, including discomfort, infection, technical extension issues such as fracture, and other morbidities. The single lead may be operable to provide medically acceptable neurostimulation coverage that treats head pain over the frontal, lateral, and posterior regions. The single lead may be operable to provide medically acceptable therapeutic neurostimulation coverage that would otherwise often require unilateral leads (six total leads if, as is common, the pain is global/holocephalic), thereby resulting in a decrease in the number of patients that require more than one associated Implantable Pulse Generator (IPG). Currently available IPGs are capable of accepting a maximum of four leads, each having the ability to cover only one anatomic region, as each lead only has one active array. The lead may include a progressively tapering diameter over the lead segment containing t three active arrays, a feature serving clinical improvements in patient comfort and cosmetics. The lead may further comprise a distal array disposed over a thin, flattened terminal portion of the lead, which is the portion intended to be positioned over the supraorbital (frontal) region, a feature serving clinical improvements in patient comfort and cosmetics.
Thus the present disclosure provides for a peripheral neurostimulation lead that is uniquely designed for subcutaneous implantation in the head as a therapy for chronic head pain, and is designed to solve the known design issues associated with current leads, as the lead of the present disclosure seeks to optimize the therapeutic response, improve patient comfort, improve cosmetics, reduce the number of surgical leads required, reduce medical risk, and reduce medical costs.
Turning now to the drawings, which depict the system and several of its components in various aspects and views, and in which similar reference numerals denote similar elements. The drawings illustrate an IPG from which two neurostimulating leads may extend to a length sufficient to allow for therapeutic neurostimulation unilaterally over the frontal, parietal and occipital regions. The leads include an extended plastic lead body; a plurality of surface metal electrodes disposed along the lead, which may be divided into two or more electrode arrays; a plurality of internal electrically conducting metal wires running along at least a portion of its length and individually connecting the IPG's internal circuit to individual surface metal electrodes. The implantable pulse generator includes a rechargeable battery, an antenna coil, and ASIC. The system may be operable to provide medically acceptable therapeutic neurostimulation to multiple regions of the head, including the frontal, parietal and occipital regions simultaneously, and three figures demonstrate various views of this feature as the lead is depicted in-situ.
Continuing with
The plastic body member 20a is an elongated, cylindrical, flexible member, which may be formed of a medical grade plastic polymer. It has a proximal end 22, a distal end 21, and may be conceptually divided into five segments along its linear dimension. Progressing from the proximal end 22, these segments sequentially include a proximal lead segment (PLS) 22a, a parietal electrode array (PEA) 26, an inter-array interval 27, a frontal electrode array (FEA) 25, and a distal non-stimulating tip 33.
The lead internal wires 29 pass along the interior of the plastic body member as depicted in
Continuing with
Returning to
Typically, the FPL 20 is a single lead having the two arrays, 25 and 26, disposed along the length thereof. The diameter and the shape of this lead can be uniform or it can be of any shape that facilitates surgical placement of the lead. However, with a single lead, two distinct regions of the cranium can be therapeutically treated, each independently controlled by the IPG 10 via the leads 29 and each having a design via the interelectrode spacing and even the electrode configuration to facilitate the requirements of such therapeutic treatment of a particular region associated with a particular set of nerves. This, thus, requires only a single incision to feed the FPL 20 from the incision point to a particular region.
Continuing with
The plastic body member 39 is an elongated, cylindrical, flexible member, which may be formed of a medical grade plastic polymer. It has a proximal end 32 and a distal end 31. Progressing along the lead from the proximal end 32, these segments sequentially include a proximal lead segment (PLS) 32a, an occipital electrode array (OEA) 35, and a distal non-stimulating tip 33.
As depicted in
Referring to
Battery 12 is connected to the ASIC 13 via a connection that is flexible. The overall enclosure for the battery 12, antenna 11 and ASIC 13 has a very low flat profile (seen in a top view in
The ASIC 13 is operable to interface with the lines 29 in the FPL 20 and the lines 39 in the OL 34 driving the respective SMEs 24, 34. The ASIC 13 is a state machine that is configured to provide stimulation signals in the form of pulses, variable frequencies, etc., to the respective electrodes in accordance with a predetermined program. Once the program is loaded and initiated, the state machine will execute the particular programs to provide the necessary therapeutic stimulation. The ASIC 13 has memory associated there with and a communication capability, in addition to charge control to charge battery 12. Each of the set of wires 29 and 39 interface with the ASIC 13 such that the ASIC 13 individually controls each of the wires in the particular bundle of wires. Thus, each electrode in each of the arrays, 25, 26 and 35, can be individually controlled. As noted hereinabove, each electrode can be designated as an anode or a cathode, or it can even be turned off.
During a charging operation, the IPG 10 is interfaced with an external charging unit via the antenna 11 which is coupled to a similar antenna or coil in the external charging unit (not shown). The charging operation is controlled by the ASIC 13, as the battery 12, in one embodiment, can include the use of a lithium ion battery. It is important for power management to control the amount of charge delivered to the battery, the charging rate thereof and to protect the battery 12 from being overcharged.
Additionally, the ASIC 13 is capable of communicating with an external unit, typically part of the external charging unit, to transfer information thereto and receive information there from. In this manner, configuration information can be downloaded to the ASIC 13 and status information can be retrieved therefrom. Although not illustrated herein, a headset or the such is provided for such external charging/communication operation.
The system may include a unibody construction to provide physical and functional continuity of the related components and sub-components. This unibody construction is basically an enclosure that encloses the entire IPG and the interface with the FPL 20 and the OL 30. The FPL 20 and the OL 30 are separate assemblies that are attached to the ASIC 13 via either a connector or via a hardwired connection. The FPL 20 and the OL 30 are totally enclosed and sealed with only the distal end of leads 29, 39 extending therefrom. Once attached to the ASIC 13, or the PC board associated there with, a material is disposed about the entire IPG 10 to provide a seal therefore which extends over the IPG 10 and the proximal ends 22 and 32 of the FPL 20 and OL 30, respectively. With such a unibody construction, a surgeon need only make one incision to subcutaneously insert the entire assembly including both the IPG 10 and associated leads in a desired region in the cranium, typically just behind the parietal bone and slightly above the mastoid bone and the pinna. This allows the FPL 20 to be fed around toward the frontal bone and the OL 30 to be fed backwards toward the occipital bone. Thus, the entire neurostimulator system will be disposed subcutaneously about the cranium and will require no anchor. Without the requirement for an anchor, there is no protuberance required in the IPG 10, allowing the IPG 10 to be completely sealed. This is facilitated by the fact that very little movement will occur with respect to the tissue surrounding the IPG 10 after implantation thereof. Due to this minimal amount of movement, no stylet will be required (but such can be incorporated if desired) to secure either the FPL 20 or the OL 30 in place to underlying facia.
The overall mechanistic purpose of an implantable neurostimulation system is to generate and conduct a prescribed electrical pulse wave from an IPG 10 down a set of lead internal wires 29, 38 running a portion of the length of the lead to specified programmed set of SME 24, 34, whereby the current is then conducted by tissue and/or fluid to an adjacent, or nearby, set of one or more SME 24, 34, which in turn passes the signal proximally down the lead wire 29, 38 back to the IPG 10 and its ASIC 13, thus completing the circuit.
The first embodiment provides for the implantation of the neurostimulator system that incorporates one or more of the features outlined above and includes a head-mounted located, unibody neurostimulating system comprising an IPG 10 and at least two neurostimulating leads (FPL 20 and OL 30). The system may be implanted in a manner such that the IPG 10 and two leads 20, 30 are subcutaneously disposed as illustrated in
In this embodiment, the leads are constructed as described above and as depicted in the drawings. The FPL 20 is approximately 26 cm in length from its proximal end 22 to its distal end 21. The FPL 20 has a distal non-stimulating tip of approximately 3 mm in length that abuts the FEA, which may have ten SME 24 uniformly disposed over approximately 8 cm. This is followed by an inter-array interval 27 of approximately 4 cm, then the PEA, which may include eight SME 24 uniformly disposed over approximately 6 cm, and finally a proximal lead segment 22a that ends at the proximal end 22, where the lead transitions to the IPG 10 and the lead internal wires 29, 38 connect to the ASIC 13.
In this embodiment, the occipital lead may comprise a plastic body member 39 over which six SME 34 may be disposed uniformly over approximately a 10 cm length of the lead, and the lead terminates in approximately a 3 mm distal non-stimulating tip 33.
In this embodiment, the IPG 10 comprises the elements described above and depicted in the drawings, including an ASIC 13, a rechargeable battery 12, and an antenna 11, which all may be housed in a medical grade metal can with plastic cover 14. In this embodiment the dimensions of the IPG 10 measured along the outer surface of the plastic cover 14 may be approximately 5 cm by 3 cm by 0.5 mm.
The system includes a portable programmer 40 and a portable recharging unit, both of which functionally couple to the IPG through a radiofrequency mechanism.
In this embodiment, the system is capable of handling a program from the portable programmer 40 that includes such parameters as pulse amplitude, frequency and pulse width.
The procedure itself involves the permanent subcutaneous implantation of an IPG with multilead, multi-array neurostimulator system. The patient may have had a period of trial neurostimulation, which is standard in traditional neurostimulator evaluations but is optional here. The actual permanent implant takes place in a standard operating suite with appropriate sterile precautions and is typically performed under general anesthesia with the patient positioned prone with the hair and body prepped and draped.
While the IPG may be positioned subcutaneously anywhere over the head or upper cervical region, in this embodiment it is positioned above and behind the ear. Thus, at a position approximately 1-2 cm above the ear and a couple of cm posterior to the ear, a Supraorbital Incision of sufficient length (approximately 4-6 cm) is made to a depth sufficient to reach the subcutaneous layer. At the posterior aspect of this incision a pocket to accept the IPG is fashioned by standard dissection techniques. The pocket should be 10-20% larger than the IPG itself to allow for a comfortable fit and no undue tension on the overlying skin and/or incision. A second approximately 1-2 cm incision is made to the subcutaneous layer at a point above and anterior to the pinna of the ear in the temple region.
In this embodiment, in the supra-auricular incision, a tubular introducer with a plastic-peel away shell (Peel-Away Introducer) is advanced subcutaneously from the supra-auricular incision to the temple incision. The FL is then passed per the introducer, whereby the peel-away shell is removed leaving the proximal segment of the FL in position in the subcutaneous layer. A new Peel-Away introducer is then advanced subcutaneously from the Temple Incision medially and commonly 1-2 cm above the eyebrow to its final position where the distal tip of the lead approximates the midline; a position that results in the frontal electrode array (FEA) over the superficial nerves of the frontal region.
In this embodiment, and prior to activation thereof, the IPG is next positioned in the previously fashioned subcutaneous pocket posterior to the supra-auricular incision. Then, from the inferior aspect of the supra-auricular incision a new peel-away introducer is advanced subcutaneously medially, and inferiorly to cross the nerve region of the occipital region such that the distal tip of the introducer approximates the midline. Per the introducer the OL is passed, whereby the Peel-Away Introducer is then removed, leaving the lead in position with its active array over the superficial nerves of the occipital region.
Following the entire placement of the complete system, including the IPG and both leads and suturing, the neurostimulator unit is then powered-up and its circuits checked. Upon recovery from anesthesia the system is turned on for the patient with a portable programmer and the multiple parameters for the system programmed to an optimal therapeutic endpoint for the patient.
In this embodiment, the implantable unit contains a multi-year battery that is capable of being recharged from an external source.
In this embodiment, the system is capable of handling a program from the portable programmer 40 that includes such parameters as pulse amplitude, frequency and pulse width. The system is charge balanced, current controlled, and rechargeable at preferably intervals that exceed one week. The preferred stimulation paradigm may be current controlled, voltage controlled, or a combination of both. The pulsing may be charge balanced or charge imbalanced. The preferred work cycle is between 10 and 100%.
Turning now to
Turning to
Turning to
It should be noted that the in some embodiments of IPG 10, including variations of those illustrated in
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Variations of the embodiment of the IPG 10 illustrated in
Turning now to
Turning to
The illustrated image includes an image of the left side of the head that is divided into three sections. There is a first frontal section including the supraorbital nerve region, a medial section including the parietal nerve region and a distal section that includes the occipital nerves. As noted herein, the programmer 40 is operable to interface through a headset or external charging/communication circuit (not shown) with one or more implanted neurostimulator systems. Thus, there is provided a display area 43 in the LCD display for depicting the recharge level of the Programmer 40 and a display area 42 for depicting the charge level of each neurostimulator system, one for the left and one for the right, if two neurostimulator systems are implanted and being monitored. For each section of the displayed head image, the frontal, the medial and the distal, there is illustrated a percentage of value illustrating the percentage level of stimulation that is being applied. There are provided left and right toggle buttons 45 that allow a particular section to be selected and increase/decreased buttons 46 to increase and decrease the level of stimulation. A confirm button 47 is provided for actually entering information after selection thereof. A lot button is disposed on the upper side, as illustrated in
Thus, the procedure to implant, in summary, is to first provide a neurostimulator system that has a unibody construction comprised of an IPG integrated with the leads as opposed to a separate system wherein the leads are implanted first, positioned, activated and then connected to the IPG. Then the IPG implanted into an associated pocket. With the unibody construction of the disclosed neurostimulator system, this requires each of the multiple leads to first be positioned proximate to a desired nerve region through one or more incisions through the subcutaneous layer. This typically involves a single initial incision that is associated with the subcutaneous pocket for the IPG, wherein the leads are first inserted through the incision to the particular nerve region subcutaneously and then the IPG disposed within the pocket subcutaneously. However, the IPG is not secured to an underlying structure, such as bone or fascia. The reason for this is that the IPG is, first, very lightweight, and second, disposed in an area of the skull that is subject to very little movement, thus minimizing the possibility of any migration of the leads.
There are multiple alternate embodiments that preserve the features of the neurostimulation system disclosed herein, which include an externally rechargeable and programmable IPG, sized and configured for implantation in the head, and from which fronto-parietal and occipital leads, along with their respect surface metal electrode arrays, extend to cover multiple regions of the head. In various embodiments, the spacing and dimensions of the electrode array(s) for each specific array may be constant, or the electrode arrays may be specifically designed with respect to electrode type, dimensions, and layout for improving the therapeutic effectiveness for the specific cranial region it is to be associated with. The multiple alternate embodiments also include a subcutaneously positioned unibody neurostimulator device that contains an IPG and two leads, one with a single electrode array and the other with two electrode arrays.
Thus, the disclosure comprises extended electrode array designs (two or more regions by a single lead), and/or multiple arrays and optimized intra-array electrode dispositions. The disclosure also comprises lead configurations, which include the capability of a modular lead design that provides for ports on either the standard FPL and OLs. In another embodiment, the IPG may receive additional separate leads, if and as necessary either at the time of initial implant or in the future.
Further, the lead lengths, along with the specific technical makeup and dimensions of the individual surface metal electrodes and electrode arrays, may be varied to include more or less than three unilateral regions of the head (occipital, parietal, and frontal) contemplated by the first embodiment. For example, a single IPG may energize and control multiple additional leads of varying lengths that ultimately could be disposed over virtually every region of the head and face bilaterally, to thus cover multiple and disparate regions, with each of these leads and arrays of electrodes associated therewith designed for a particular cranial region. Further, each of these leads can have one or more disparate arrays associated therewith so as to accommodate more than a single cranial region, this single multi-array lead allowing a single incision to accommodate these multiple regions.
At least two electrodes may be included per region (and thus over array), and while the first embodiment calls for a total of 24 electrodes disposed over three arrays covering three different regions of the head—the occipital, parietal and frontal regions—there is no absolute limit to the maxim (or minimum) number of electrodes. Similarly, while the first embodiment calls for three electrode arrays, the disclosure contemplates two, or even one array (so long as the arrays covers at least two regions). There is also no limiting maximum for the number of arrays. Also, there may be multiple variations of design within each separate array, including for example, variations in the number, dimensions, shape, and metal composition of the individual electrodes, as well as the distance and constancy of distance between electrodes, within each array. Further, each array may have the same or completely different designs.
While the neurostimulation system has been described for subcutaneous implantation as a peripheral neurostimulator in the head and for head pain, it is capable of being implanted and used as a peripheral nerve stimulator over other regions of the head and face than described above and also over other peripheral nerves in the body.
In another embodiment the IPG may be positioned subcutaneously over virtually any other point of the head that can accept the unit.
In another embodiment the leads may be passed such that their respective electrode arrays over positioned subcutaneously over other painful regions of the face, head and neck.
In another embodiment the leads may be passed by measures other than a standard Peel-Away Introducer. For example they may be passed per the previous retrograde positioning of a standard, metal tubular introducer, which is then removed over the lead once it has been positioned.
While a common embodiment includes the implantation of two neurostimulator systems (one on each side), other embodiments may include only system or may include more than two systems. These would depend upon the nature, location and extension of a patient's pain report.
While the neurostimulation system has been described for implantation as a peripheral neurostimulator in the head and for head pain, it is capable of being implanted and used as a peripheral nerve stimulator over other regions of the head and face than described above and also over other peripheral nerves in the body.
When functioning; that is when the internal circuit of lead internal wires is connected to an IPG; the SMEs of the various arrays are programmed to function as anodes and cathodes. The ASIC 13 then drives with a generated electrical pulse wave then passes from the ASIC of the IPG to the associated internal lead wire, and ultimately to its associated terminal surface metal electrode. The current then passes a short distance from the subcutaneous tissue, within which the neurostimulator system is implanted, to a contiguous, or nearby, electrode, whereby it passes back up the lead to its associated proximal metal contact, and then back to the IPG and the ASIC 13 to complete the circuit. The generated pulse waves pass through the subcutaneous tissue between two terminal electrodes that stimulate the sensory nerves of the area. As noted hereinabove, the configuration for the ASIC 13 can define certain of the SMEs as anodes and certain of the SMEs as cathodes. When active, the IPG may be programmed to produce continuous series of pulse waves of specified frequency, amplitude, and pulse width. It is this series of pulse waves actively stimulating a patient's locally associated nerves that underpins the therapeutic effect of the implanted unit. The electrical pulse wave then passes from a connected proximal surface metal contact, along the associated internal lead wire, and ultimately to its associated terminal surface metal contact.
With respect to
It is to be understood that the implementations disclosed herein are not limited to the particular systems or processes described which might, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular implementations only, and is not intended to be limiting. As used in this specification, the singular forms “a”, “an” and “the” include plural referents unless the content clearly indicates otherwise. Thus, for example, reference to “an accumulator” includes a combination of two or more accumulators; and, reference to “a valve” includes different types and/or combinations of valves. Reference to “a compressor” may include a combination of two or more compressors. As another example, “coupling” includes direct and/or indirect coupling of members.
Although the present disclosure has been described in detail, it should be understood that various changes, substitutions and alterations may be made herein without departing from the spirit and scope of the disclosure as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present disclosure. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
Referring now to
Turning now to
The plastic body member 2409 is an elongated, cylindrical, flexible member, which may be formed of a medical grade plastic polymer. It has a proximal end 2402 and a distal end 2401. Progressing along the lead from the proximal end 2402, these segments sequentially include a proximal lead segment 2402a, an infraorbital electrode array (IEA) 2405, and a distal non-stimulating tip 2403.
Staying with
Turning to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning next to
Turning now to
The plastic body member 3309 is an elongated, cylindrical, flexible member, which may be formed of a medical grade plastic polymer. It has a proximal end 3302 and a distal end 3301. Progressing along the lead from the proximal end 3302, these segments sequentially include a proximal lead segment 3302a, a mandibular electrode array (MEA) 3305, and a distal non-stimulating tip 3303.
Staying with
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning next to
Turning to
It should be noted that not all embodiments of the neurostimulation system which include a ML 3300 will require both the incision 3802 and the incision 3804 for implantation. Some embodiments will only require the incision 3802, while other embodiments will only require the incision 3804. Also, the exact positions of one or both of the incisions 3802, 3804 will be different in different embodiments and may also depend on the particular patient and surgeon.
Referring now to
Referring now to
Referring now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
As is illustrated in
It should be noted that in some embodiments, a very thin layer of silicone is applied to the surfaces of the ASIC body 306 and of the battery body 322 before the IPG is placed in the mold 5002. Applying a thin layer of silicone will provide a flexible barrier between the IPG 10 components and the epoxy coatings 324. This can help avoid problems associated with the IPG 10 components and the epoxy coatings 324 expanding and contracting at different rates as they heat up and cool down. This thin layer can be formed by a spray or dipping, such that the layer is conformal. Prior to forming this thin coating, the entire surface is cleaned with an appropriate solvent such as acetone.
Turning now to
Turning now to
Turning now to
Turning now to
Turning now to
Turning next to
Turning now to
Turning now to
Turning now to
It should be noted that, while the embodiment of the IPG 10 depicted in
Turning now to
The IPG 10 includes an enclosure or “can” 6002 which houses a battery 6502 and a printed circuit board 6504 (see, e.g.,
Turning now to
The purpose of the recessed portion 6106 is to allow the IPG 10 to have a low-profile configuration, i.e., a footprint or shape. In one embodiment, recessed portion 6106 has a depth rd of approximately 0.1 inches, a width rw of approximately 0.39 inches and a length rl of approximately 0.57 inches. Thus, recessed portion 6106 comprises approximately 25% of the surface area of top side 6104 of top piece 6102 of can 6002. The recessed portion 6106 is connected to the top side 6104 of can 6002 by an interior connecting wall 6108 that extends between interior edges 6114 and 6115 of bottom wall 6118 of recessed portion 6106 and interior edges 6120 and 6122 of top side 6104, with the remaining two exterior sides of the recessed portion open. As described herein below, the recessed portion 6106 with two exterior open sides allows room for connections to be positioned on the exterior of the can 6002 below the plane defined by the top side 6104 of the top piece 6102 without protruding above the top side.
In the embodiment illustrated in
Referring next to
Turning next to
Turning to
In some embodiments, the feedthroughs 6004, 6005 are pre-assembled (with the terminals 6304 and the associated electrically conductive pins already inserted) and then welded into the cut-outs 6110, 6112. In some embodiments, welding the feedthroughs 6004 into the cut-outs 6110, 6112 includes laser welding. Different embodiments use different materials for the various components of the feedthroughs 6004, 6005. In some embodiments, the pins 6306 will be electrically conductive materials other than platinum-iridium, such as any other conductive metal. An advantage of using platinum-iridium pins 6306, however, is that platinum-iridium is conductive, bio-compatible, and very stable. It is important to note that the environment external to the can 6002 is a potentially oxidative environment and it is important that oxide not contaminate any portion of the IPG, even though the IPG is sealed with a silicone based material. Any material that is external to the can must be capable of existing in the environment and resisting any oxidation, if possible.
Turning now to
Turning now to
Turning next to
It can be seen that the can 6002 must be at least as thick as the thickest component to be housed within it. In the embodiment illustrated in
Turning now to
Turning now to
Turning now to
It should be noted that a feature of the illustrated embodiment is that the wires 6904 are soldered onto the metal sleeves 6092 in such a way that the wires extend roughly perpendicular from the metal sleeves and metal pins 6303 and pass through an open side of recessed portion 6106 of can 6002 at a first end 6107 of the can, as opposed to be being soldered onto the sleeves such that the wires extend upwardly away from the flat portions 6302 of the feedthroughs 6004, 6005. This feature avoids having the wires extend up beyond the plane created by an extension of the non-recessed portion of the top side 6104 of the top piece 6102 of the can 6002. This, in turn, helps ensure the IPG 10 has a low-profile shape.
Turning next to
Also of note in the embodiment illustrated in
Turning next to
Turning now to
In some embodiments, the silicone layer 6006 includes one or more lobes 7102 on one or both ends of the IPG 10. These lobes 7102 are angled down slightly to better conform to a patient's head when the IPG 10 is implanted. As illustrated, can 6002 is encapsulated in a center portion or section 7104 with coil 6010 encapsulated in one of the lobes 7102 at the first end 6107 of the can with the linear side of the coil proximate to and parallel to the first end 6107 of can 6002 with leads 20, 30 extending proximate to and across the coil.
Turning to
As is seen in
Referring again to
Further, since the leads 20 and 30 extend from one side of can 6002 and make a bend before extending out along a longitudinal axis of the overall IPG, the silicone that covers the entire IPG (see
It will be appreciated by those skilled in the art having the benefit of this disclosure that this implantable head mounted neurostimulation system for head pain provides a unibody construction with implanted leads to cover the frontal, parietal, and occipital regions of the head. It should be understood that the drawings and detailed description herein are to be regarded in an illustrative rather than a restrictive manner, and are not intended to be limiting to the particular forms and examples disclosed. On the contrary, included are any further modifications, changes, rearrangements, substitutions, alternatives, design choices, and embodiments apparent to those of ordinary skill in the art, without departing from the spirit and scope hereof, as defined by the following claims. Thus, it is intended that the following claims be interpreted to embrace all such further modifications, changes, rearrangements, substitutions, alternatives, design choices, and embodiments.
This application is a continuation of U.S. patent application Ser. No. 16/198,216, filed Nov. 21, 2019, entitled “LOW PROFILE HEAD-LOCATED NEUROSTIMULATOR AND METHOND OF FABRICATION”, which is a continuation-in-part of U.S. patent application Ser. No. 15/599,206, filed on May 18, 2017, entitled SURGICAL METHOD FOR IMPLANTABLE HEAD MOUNTED NEUROSTIMULATION SYSTEM FOR HEAD PAIN. U.S. patent application Ser. No. 15/599,206 is a continuation-in-part of U.S. patent application Ser. No. 14/879,943, filed on Oct. 9, 2015, entitled SURGICAL METHOD FOR IMPLANTABLE HEAD MOUNTED NEUROSTIMULATION SYSTEM FOR HEAD PAIN, which published on Feb. 4, 2016 as U.S. Application Publication No. 2016-0030746, and which issued on Feb. 6, 2018, as U.S. Pat. No. 9,884,190. U.S. patent application Ser. No. 14/879,943 is a continuation-in-part of U.S. patent application Ser. No. 14/717,912, filed May 20, 2015 and entitled IMPLANTABLE HEAD MOUNTED NEUROSTIMULATION SYSTEM FOR HEAD PAIN, which issued on May 22, 2018, as U.S. Pat. No. 9,974,968. U.S. patent application Ser. No. 14/717,912 is a continuation of U.S. patent application Ser. No. 14/460,139, filed Aug. 14, 2014 and published on Apr. 23, 2015 as U.S. Patent Application Publication No. 2015-0112406, now U.S. Pat. No. 9,042,991, issued on May 26, 2015. U.S. patent application Ser. No. 14/460,139 claims benefit of U.S. Provisional Application No. 61/894,795, filed Oct. 23, 2013, entitled IMPLANTABLE HEAD MOUNTED NEUROSTIMULATION SYSTEM FOR HEAD PAIN. This application also claims priority to and the benefit of U.S. Provisional Application No. 62/589,380, filed Nov. 21, 2017, and entitled LOW PROFILE HEAD-LOCATED NEUROSTIMULATOR AND METHOD OF FABRICATION U.S. application Ser Nos. 15/599,206, 14/879,943, 14/717,912, 14/460,139, 61/894,795, and 62/589,380, and U.S. Patent Application Publication Nos. 2016-0030746, 2015-0112406, and U.S. Pat. Nos. 9,884,190, 9,974,968, and 9,042,991 are incorporated by reference herein in their entirety. U.S. patent application Ser. No. 15/599,206 is also related to U.S. patent application Ser. No. 14/460,111, filed Aug. 14, 2014, published on Feb. 19, 2015 as U.S. Patent Application Publication No. 2015-0051678, entitled IMPLANTABLE NEUROSTIMULATION LEAD FOR HEAD PAIN, now U.S. Pat. No. 9,427,566 issued on Aug. 30, 2016. U.S. patent application Ser. No. 14/460,111 claims benefit of U.S. Provisional Application No. 61/865,893, filed Aug. 14, 2013. U.S. application Ser. Nos. 14/460,111 and 61/865,893 and U.S. Patent Application Publication No. 2015-0051678 and U.S. Pat. No. 9,427,566 are incorporated by reference herein in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
3727616 | Lenzkes | Apr 1973 | A |
3908668 | Bolduc | Sep 1975 | A |
4441498 | Nordling | Apr 1984 | A |
4495917 | Byers | Jan 1985 | A |
4612934 | Borkan | Sep 1986 | A |
4793353 | Borkan | Dec 1988 | A |
4819647 | Byers et al. | Apr 1989 | A |
5000194 | van den Honert et al. | Mar 1991 | A |
5037497 | Stypulkowski | Aug 1991 | A |
5215086 | Terry, Jr. et al. | Jun 1993 | A |
5279292 | Baumann et al. | Jan 1994 | A |
5545219 | Kuzma | Aug 1996 | A |
5569307 | Schulman et al. | Oct 1996 | A |
5615100 | Radecker et al. | Mar 1997 | A |
5733313 | Barreras, Sr. et al. | Mar 1998 | A |
5876425 | Gord et al. | Mar 1999 | A |
5905646 | Crewson et al. | May 1999 | A |
6016449 | Fishell et al. | Jan 2000 | A |
6088619 | Hein et al. | Jul 2000 | A |
6154677 | Leysieffer | Nov 2000 | A |
6178353 | Griffith et al. | Jan 2001 | B1 |
6236892 | Feler | May 2001 | B1 |
6246911 | Seligman | Jun 2001 | B1 |
6456883 | Torgerson et al. | Sep 2002 | B1 |
6516227 | Meadows et al. | Feb 2003 | B1 |
6529774 | Greene | Mar 2003 | B1 |
6597954 | Pless et al. | Jul 2003 | B1 |
6606521 | Paspa et al. | Aug 2003 | B2 |
6618623 | Pless et al. | Sep 2003 | B1 |
6639344 | Bucher et al. | Oct 2003 | B2 |
6895283 | Erickson et al. | May 2005 | B2 |
6920359 | Meadows et al. | Jul 2005 | B2 |
7110819 | Ohara | Sep 2006 | B1 |
7127298 | He et al. | Oct 2006 | B1 |
7171273 | Shaquer | Jan 2007 | B2 |
7319906 | Kuzma et al. | Jan 2008 | B2 |
7437197 | Harris et al. | Oct 2008 | B2 |
7499755 | Cross, Jr. | Mar 2009 | B2 |
7599743 | Hassler, Jr. et al. | Oct 2009 | B2 |
7676273 | Goetz et al. | Mar 2010 | B2 |
7706892 | Colvin et al. | Apr 2010 | B2 |
7729781 | Swoyer et al. | Jun 2010 | B2 |
7769461 | Whitehurst et al. | Aug 2010 | B2 |
7894905 | John et al. | Feb 2011 | B2 |
8027735 | Tziviskos et al. | Sep 2011 | B1 |
8030798 | Seligman | Oct 2011 | B2 |
8140152 | John et al. | Mar 2012 | B2 |
8165678 | Forsberg et al. | Apr 2012 | B2 |
8352046 | Haller et al. | Jan 2013 | B1 |
8412334 | Whitehurst et al. | Apr 2013 | B2 |
8457744 | Janzig et al. | Jun 2013 | B2 |
8504163 | Meadows | Aug 2013 | B1 |
8509876 | Karmarkar | Aug 2013 | B2 |
8515541 | Jaax et al. | Aug 2013 | B1 |
8538545 | Meskens | Sep 2013 | B2 |
8543212 | Merfeld et al. | Sep 2013 | B2 |
8634909 | Zimmerling et al. | Jan 2014 | B2 |
8639344 | Greenberg et al. | Jan 2014 | B2 |
8639391 | Alberth, Jr. et al. | Jan 2014 | B1 |
8649880 | Parker, Jr. | Feb 2014 | B1 |
8718779 | Whitehurst et al. | May 2014 | B2 |
8774924 | Weiner | Jul 2014 | B2 |
8812113 | Mashiach | Aug 2014 | B2 |
8958880 | Degiorgio et al. | Feb 2015 | B2 |
8972015 | Stack et al. | Mar 2015 | B2 |
9020589 | Torgerson | Apr 2015 | B2 |
9031662 | Leigh et al. | May 2015 | B2 |
9042991 | Reed et al. | May 2015 | B2 |
9061139 | Stevenson et al. | Jun 2015 | B2 |
9095699 | Rosenberg et al. | Aug 2015 | B2 |
9101732 | Dadd et al. | Aug 2015 | B2 |
9119957 | Gantz et al. | Sep 2015 | B2 |
9403024 | Bunyan et al. | Aug 2016 | B2 |
9421387 | Hazard et al. | Aug 2016 | B2 |
9498635 | Dellamano et al. | Nov 2016 | B2 |
9498636 | Dellamano et al. | Nov 2016 | B2 |
9539432 | Dellamano et al. | Jan 2017 | B2 |
9717917 | Dellamano et al. | Aug 2017 | B2 |
9833629 | Dellamano et al. | Dec 2017 | B2 |
9839788 | Dellamano et al. | Dec 2017 | B2 |
9884190 | Reed et al. | Feb 2018 | B2 |
9889308 | Dellamano et al. | Feb 2018 | B2 |
9974968 | Reed et al. | May 2018 | B2 |
10258805 | Reed et al. | Apr 2019 | B2 |
10416252 | Liu | Sep 2019 | B2 |
10695571 | Dellamano et al. | Jun 2020 | B2 |
10850112 | Reed et al. | Dec 2020 | B2 |
10946205 | Reed et al. | Mar 2021 | B2 |
10960215 | Reed | Mar 2021 | B2 |
11357995 | Dellamano et al. | Jun 2022 | B2 |
11400302 | Reed et al. | Aug 2022 | B2 |
20020032471 | Loftin et al. | Mar 2002 | A1 |
20020116042 | Boling | Aug 2002 | A1 |
20030114899 | Woods et al. | Jun 2003 | A1 |
20040215280 | Dublin | Oct 2004 | A1 |
20050004637 | Singhal et al. | Jan 2005 | A1 |
20050020873 | Berrang et al. | Jan 2005 | A1 |
20050027192 | Govari et al. | Feb 2005 | A1 |
20050030774 | Vazquez | Feb 2005 | A1 |
20050075696 | Forsberg et al. | Apr 2005 | A1 |
20050102006 | Whitehurst et al. | May 2005 | A1 |
20050182470 | Cross | Aug 2005 | A1 |
20050209667 | Erickson et al. | Sep 2005 | A1 |
20050288741 | Hassler et al. | Dec 2005 | A1 |
20060122664 | Sacha et al. | Jun 2006 | A1 |
20060206166 | Weiner | Sep 2006 | A1 |
20060222942 | Zhao | Oct 2006 | A1 |
20060241717 | Mcgivern et al. | Oct 2006 | A1 |
20060247754 | Greenberg et al. | Nov 2006 | A1 |
20060293723 | Whitehurst et al. | Dec 2006 | A1 |
20070049988 | Carbunaru et al. | Mar 2007 | A1 |
20070073357 | Rooney et al. | Mar 2007 | A1 |
20070097719 | Parramon et al. | May 2007 | A1 |
20070112404 | Mann et al. | May 2007 | A1 |
20070203545 | Stone et al. | Aug 2007 | A1 |
20070255338 | Wahlstrand | Nov 2007 | A1 |
20080039916 | Colliou et al. | Feb 2008 | A1 |
20080132979 | Gerber | Jun 2008 | A1 |
20080183253 | Bly | Jul 2008 | A1 |
20080268720 | Ries | Oct 2008 | A1 |
20080268729 | Yomo et al. | Oct 2008 | A1 |
20080269716 | Bonde et al. | Oct 2008 | A1 |
20080300657 | Stultz | Dec 2008 | A1 |
20090018619 | Skelton et al. | Jan 2009 | A1 |
20090058635 | LaLonde et al. | Mar 2009 | A1 |
20090069869 | Stouffer et al. | Mar 2009 | A1 |
20090105557 | Najafi et al. | Apr 2009 | A1 |
20090209945 | Lobl et al. | Aug 2009 | A1 |
20090210028 | Rigaux et al. | Aug 2009 | A1 |
20090216324 | Leigh et al. | Aug 2009 | A1 |
20090270951 | Kallmyer | Oct 2009 | A1 |
20090312769 | Dadd et al. | Dec 2009 | A1 |
20100110741 | Lin et al. | May 2010 | A1 |
20100114249 | Wahlstrand et al. | May 2010 | A1 |
20100161004 | Najafi et al. | Jun 2010 | A1 |
20100168818 | Barror et al. | Jul 2010 | A1 |
20100174341 | Bolea et al. | Jul 2010 | A1 |
20100274313 | Boling et al. | Oct 2010 | A1 |
20100331922 | DiGiore et al. | Dec 2010 | A1 |
20110009925 | Leigh | Jan 2011 | A1 |
20110046699 | Mazanec | Feb 2011 | A1 |
20110093047 | Davis et al. | Apr 2011 | A1 |
20110106210 | Meskens | May 2011 | A1 |
20110106220 | Degiorgio et al. | May 2011 | A1 |
20110112603 | Degiorgio et al. | May 2011 | A1 |
20110172736 | Gefen et al. | Jul 2011 | A1 |
20110190849 | Faltys et al. | Aug 2011 | A1 |
20120041515 | Meskens et al. | Feb 2012 | A1 |
20120071936 | Pianca et al. | Mar 2012 | A1 |
20120078327 | Sloan et al. | Mar 2012 | A1 |
20120078337 | Darley et al. | Mar 2012 | A1 |
20120078338 | Sheraton | Mar 2012 | A1 |
20120112556 | Forsell | May 2012 | A1 |
20120197375 | Pianca et al. | Aug 2012 | A1 |
20120215218 | Lipani | Aug 2012 | A1 |
20120274270 | Dinsmoor et al. | Nov 2012 | A1 |
20120277621 | Gerber et al. | Nov 2012 | A1 |
20120277823 | Gerber et al. | Nov 2012 | A1 |
20130057364 | Kesler et al. | Mar 2013 | A1 |
20130085542 | Mashiach | Apr 2013 | A1 |
20130085561 | Mashiach | Apr 2013 | A1 |
20130011021 | North | May 2013 | A1 |
20130116763 | Parker et al. | May 2013 | A1 |
20130131754 | Sarvazyan | May 2013 | A1 |
20130165996 | Meadows et al. | Jun 2013 | A1 |
20130197613 | Kelly et al. | Aug 2013 | A1 |
20130198531 | Hansen et al. | Aug 2013 | A1 |
20130238067 | Baudino | Sep 2013 | A1 |
20130241306 | Dupont et al. | Sep 2013 | A1 |
20130282086 | Mcdonald et al. | Oct 2013 | A1 |
20130289662 | Olson et al. | Oct 2013 | A1 |
20130333918 | Lotfi | Dec 2013 | A1 |
20140012349 | Zimmerling | Jan 2014 | A1 |
20140070808 | Reykowski et al. | Mar 2014 | A1 |
20140135882 | Prasannakumar et al. | May 2014 | A1 |
20140135886 | Cook et al. | May 2014 | A1 |
20140142669 | Cook et al. | May 2014 | A1 |
20140148883 | Stack et al. | May 2014 | A1 |
20140200631 | Carbunaru et al. | Jul 2014 | A1 |
20140214123 | Janssen et al. | Jul 2014 | A1 |
20140222125 | Glenn et al. | Aug 2014 | A1 |
20140292327 | Griswold et al. | Oct 2014 | A1 |
20140303685 | Rosenberg et al. | Oct 2014 | A1 |
20140343626 | Thenuwara et al. | Nov 2014 | A1 |
20150025613 | Nyberg, II et al. | Jan 2015 | A1 |
20150051678 | Reed et al. | Feb 2015 | A1 |
20150087892 | Tourrel et al. | Mar 2015 | A1 |
20150112406 | Reed et al. | Apr 2015 | A1 |
20150134036 | Moazen et al. | May 2015 | A1 |
20150157862 | Greenberg et al. | Jun 2015 | A1 |
20150280444 | Smith et al. | Oct 2015 | A1 |
20150303806 | Madsen et al. | Oct 2015 | A1 |
20150321004 | Reed et al. | Nov 2015 | A1 |
20160008602 | Perryman et al. | Jan 2016 | A1 |
20160030746 | Reed et al. | Feb 2016 | A1 |
20160036244 | Griffith | Feb 2016 | A1 |
20160082249 | Thenuwara et al. | Mar 2016 | A1 |
20160114174 | Colvin et al. | Apr 2016 | A1 |
20160114175 | Colvin et al. | Apr 2016 | A1 |
20160114177 | Colvin et al. | Apr 2016 | A1 |
20160166828 | Yu | Jun 2016 | A1 |
20160235993 | Cryer et al. | Aug 2016 | A1 |
20160242685 | Dehennis et al. | Aug 2016 | A1 |
20170056646 | Sibary et al. | Mar 2017 | A1 |
20170113054 | Dellamano et al. | Apr 2017 | A1 |
20170252568 | Reed | Sep 2017 | A1 |
20180221664 | Reed et al. | Aug 2018 | A1 |
20180236245 | Dellamano et al. | Aug 2018 | A1 |
20180256903 | Reed et al. | Sep 2018 | A1 |
20190091480 | Reed et al. | Mar 2019 | A1 |
20200289833 | Dellamano et al. | Sep 2020 | A1 |
20210046319 | Reed et al. | Feb 2021 | A1 |
20210162219 | Reed et al. | Jun 2021 | A1 |
20220257956 | Dellamano et al. | Aug 2022 | A1 |
Number | Date | Country |
---|---|---|
2014340652 | Jun 2016 | AU |
2734775 | Mar 2010 | CA |
2734775 | Feb 2015 | CA |
2927581 | Apr 2015 | CA |
0007157 | Jan 1980 | EP |
3060293 | Aug 2016 | EP |
2004103465 | Dec 2004 | WO |
2008046132 | Apr 2008 | WO |
WO-2009158389 | Dec 2009 | WO |
2010085838 | Aug 2010 | WO |
WO-2015060927 | Apr 2015 | WO |
WO-2015060927 | Jul 2015 | WO |
WO-2015060927 | Sep 2015 | WO |
WO-2019104187 | May 2019 | WO |
Entry |
---|
“U.S. Appl. No. 16/887,498, Notice of Allowance dated Feb. 17, 2022”, 8 pgs. |
“U.S. Appl. No. 17/085,434, Examiner Interview Summary dated Mar. 10, 2022”, 2 pgs. |
“U.S. Appl. No. 17/085,434, Response filed Mar. 15, 2022 to Non Final Office Action dated Feb. 1, 2022”, 12 pgs. |
“U.S. Appl. No. 17/085,434, Notice of Allowance dated Apr. 6, 2022”, 8 pgs. |
“U.S. Appl. No. 17/168,525, Non Final Office Action dated Apr. 28, 2022”, 20 pgs. |
“Australian Application Serial No. 2020201635, Response filed Jun. 4, 2021 to First Examination Report dated Feb. 16, 2021”, 36 pgs. |
“Canadian Application Serial No. 3,080,611, Office Action dated Jun. 22, 2021”, 3 pgs. |
“Australian Application Serial No. 2020201635, Subsequent Examiners Report dated Jun. 23, 2021”, 3 pgs. |
“Canadian Application Serial No. 3,080,611, Response filed Aug. 13, 2021 to Office Action dated Jun. 22, 2021”, 22 pgs. |
“European Application Serial No. 18881425.5, Respoonse filed Mar. 9, 2021 to Extended European Search Report dated Dec. 7, 2020”, 25 pgs. |
“Australian Application Serial No. 2020201635, First Examination Report dated Feb. 16, 2021”, 4 pgs. |
“U.S. Appl. No. 14/460,139, Examiner Interview Summary dated Feb. 20, 2015”, 3 pgs. |
“U.S. Appl. No. 14/460,139, Non Final Office Action dated Oct. 27, 2014”, 21 pgs. |
“U.S. Appl. No. 14/460,139, Notice of Allowance dated Apr. 6, 2015”, 9 pgs. |
“U.S. Appl. No. 14/460,139, Response filed Jan. 27, 2015 to Non Final Office Action dated Oct. 27, 2014”, 18 pgs. |
“U.S. Appl. No. 14/460,139, Supplemental Amendment filed Mar. 26, 2015”, 12 pgs. |
“U.S. Appl. No. 14/717,912, Corrected Notice of Allowability dated Apr. 3, 2018”, 2 pgs. |
“U.S. Appl. No. 14/717,912, Examiner Interview Summary dated Apr. 3, 2017”, 3 pgs. |
“U.S. Appl. No. 14/717,912, Final Office Action dated Dec. 21, 2016”, 12 pgs. |
“U.S. Appl. No. 14/717,912, Non Final Office Action dated May 26, 2016”, 16 pgs. |
“U.S. Appl. No. 14/717,912, Non Final Office Action dated Jul. 11, 2017”, 13 pgs. |
“U.S. Appl. No. 14/717,912, Notice of Allowance dated Mar. 26, 2018”, 8 pgs. |
“U.S. Appl. No. 14/717,912, Preliminary Amendment filed May 20, 2015”, 7 pgs. |
“U.S. Appl. No. 14/717,912, Response filed Jan. 9, 2018 to Non Final Office Action dated Jul. 11, 2017”, 8 pgs. |
“U.S. Appl. No. 14/717,912, Response filed Jun. 2, 2017 to Final Office Action dated Dec. 21, 2016”, 9 pgs. |
“U.S. Appl. No. 14/717,912, Response filed Nov. 28, 2016 to Non Final Office Action dated May 26, 2016”, 13 pgs. |
“U.S. Appl. No. 14/879,943, 312 Amendment filed Oct. 23, 2017”, 14 pgs. |
“U.S. Appl. No. 14/879,943, Non Final Office Action dated Oct. 6, 2016”, 12 pgs. |
“U.S. Appl. No. 14/879,943, Notice of Allowance dated May 26, 2017”, 8 pgs. |
“U.S. Appl. No. 14/879,943, Notice of Allowance dated Oct. 16, 2017”, 9 pgs. |
“U.S. Appl. No. 14/879,943, PTO Response to Rule 312 Communication dated Nov. 1, 2017”, 2 pgs. |
“U.S. Appl. No. 14/879,943, Response filed May 15, 2017 to Non Final Office Action dated Oct. 6, 2016”, 14 pgs. |
“U.S. Appl. No. 14/879,943, Response filed Sep. 7, 2016 to Restriction Requirement dated Sep. 2, 2016”, 7 pgs. |
“U.S. Appl. No. 14/879,943, Restriction Requirement dated Sep. 2, 2016”, 5 pgs. |
“U.S. Appl. No. 14/989,674, 312 Amendment filed Aug. 1, 2016”, 10 pgs. |
“U.S. Appl. No. 14/989,674, Examiner Interview Summary dated Jul. 7, 2016”, 3 pgs. |
“U.S. Appl. No. 14/989,674, Non Final Office Action dated Apr. 5, 2016”, 19 pgs. |
“U.S. Appl. No. 14/989,674, Notice of Allowance dated Jul. 27, 2016”, 7 pgs. |
“U.S. Appl. No. 14/989,674, Preliminary Amendment filed Jan. 18, 2016”, 7 pgs. |
“U.S. Appl. No. 14/989,674, PTO Response to Rule 312 Communication dated Aug. 11, 2016”, 2 pgs. |
“U.S. Appl. No. 14/989,674, Response filed Jul. 5, 2016 to Non Final Office Action dated Apr. 5, 2016”, 25 pgs. |
“U.S. Appl. No. 14/990,654, 312 Amendment filed Oct. 11, 2016”, 9 pgs. |
“U.S. Appl. No. 14/990,654, Non Final Office Action dated Apr. 15, 2016”, 16 pgs. |
“U.S. Appl. No. 14/990,654, Notice of Allowance dated Aug. 8, 2016”, 8 pgs. |
“U.S. Appl. No. 14/990,654, PTO Response to Rule 312 Communication dated Oct. 20, 2016”, 2 pgs. |
“U.S. Appl. No. 14/990,654, Response filed Jul. 14, 2016 to Non Final Office Action dated Apr. 15, 2016”, 25 pgs. |
“U.S. Appl. No. 14/990,678, 312 Amendment filed Oct. 11, 2016”, 7 pgs. |
“U.S. Appl. No. 14/990,678, Non Final Office Action dated Apr. 27, 2016”, 16 pgs. |
“U.S. Appl. No. 14/990,678, Notice of Allowance dated Sep. 6, 2016”, 7 pgs. |
“U.S. Appl. No. 14/990,678, PTO Response to Rule 312 Communication dated Oct. 21, 2016”, 2 pgs. |
“U.S. Appl. No. 14/990,678, Response filed Jul. 27, 2016 to Non Final Office Action dated Apr. 27, 2016”, 24 pgs. |
“U.S. Appl. No. 15/402,090, 312 Amendment filed Oct. 20, 2017”, 3 pgs. |
“U.S. Appl. No. 15/402,090, Non Final Office Action dated Mar. 6, 2017”, 17 pgs. |
“U.S. Appl. No. 15/402,090, Notice of Allowance dated Sep. 27, 2017”, 8 pgs. |
“U.S. Appl. No. 15/402,090, PTO Response to 312 Communication dated Nov. 1, 2017”, 2 pgs. |
“U.S. Appl. No. 15/402,090, Response filed Sep. 6, 2017 to Non Final Office Action dated Mar. 6, 2017”, 28 pgs. |
“U.S. Appl. No. 15/599,206, Non Final Office Action dated May 14, 2018”, 8 pgs. |
“U.S. Appl. No. 15/599,206, Notice of Allowance dated Dec. 4, 2018”, 7 pgs. |
“U.S. Appl. No. 15/599,206, Response filed Oct. 15, 2018 to Non Final Office Action dated May 14, 2018”, 22 pgs. |
“U.S. Appl. No. 15/890,020, Examiner Interview Summary dated Jan. 21, 2020”, 4 pgs. |
“U.S. Appl. No. 15/890,020, Final Office Action dated Jan. 2, 2020”, 19 pgs. |
“U.S. Appl. No. 15/890,020, Non Final Office Action dated Apr. 17, 2020”, 8 pgs. |
“U.S. Appl. No. 15/890,020, Non Final Office Action dated Jun. 20, 2019”, 15 pgs. |
“U.S. Appl. No. 15/890,020, Non Final Office Action dated Jul. 29, 2020”, 8 pgs. |
“U.S. Appl. No. 15/890,020, Response filed Mar. 20, 2020 to Final Office Action dated Jan. 2, 2020”, 11 pgs. |
“U.S. Appl. No. 15/890,020, Response filed Jul. 1, 2020 to Non Final Office Action dated Apr. 17, 2020”, 8 pgs. |
“U.S. Appl. No. 15/890,020, Response filed Nov. 20, 2019 to Non-Final Office Action dated Jun. 20, 2019”, 9 pgs. |
“U.S. Appl. No. 15/890,020, Supplemental Notice of Allowability dated Sep. 25, 2020”, 5 pgs. |
“U.S. Appl. No. 15/892,605, Final Office Action dated Dec. 11, 2019”, 20 pgs. |
“U.S. Appl. No. 15/892,605, Non Final Office Action dated Jul. 9, 2019”, 17 pgs. |
“U.S. Appl. No. 15/892,605, Notice of Allowance dated Feb. 24, 2020”, 8 pgs. |
“U.S. Appl. No. 15/892,605, Response filed Feb. 11, 2020 to Final Office Action dated Dec. 11, 2019”, 11 pgs. |
“U.S. Appl. No. 15/892,605, Response filed Nov. 12, 2019 to Non-Final Office Action dated Jul. 9, 2019”, 12 pgs. |
“U.S. Appl. No. 15/979,165, Advisory Action dated Jun. 30, 2020”, 4 pgs. |
“U.S. Appl. No. 15/979,165, Examiner Interview Summary dated Aug. 25, 2020”, 3 pgs. |
“U.S. Appl. No. 15/979,165, Final Office Action dated Apr. 17, 2020”, 15 pgs. |
“U.S. Appl. No. 15/979,165, Non Final Office Action dated Jul. 28, 2020”, 23 pgs. |
“U.S. Appl. No. 15/979,165, Non Final Office Action dated Nov. 22, 2019”, 17 pgs. |
“U.S. Appl. No. 15/979,165, Notice of Allowance dated Nov. 19, 2020”, 9 pgs. |
“U.S. Appl. No. 15/979,165, Preliminary Amendment filed Jun. 7, 2018”, 6 pgs. |
“U.S. Appl. No. 15/979,165, Response filed Mar. 16, 2020 to Non Final Office Action dated Nov. 22, 2019”, 12 pgs. |
“U.S. Appl. No. 15/979,165, Response filed Jun. 12, 2020 to Final Office Action dated Apr. 17, 2020”, 9 pgs. |
“U.S. Appl. No. 15/979,165, Response filed Jul. 15, 2020 to Advisory Action dated Jun. 30, 2020”, 15 pgs. |
“U.S. Appl. No. 15/979,165, Response filed Nov. 4, 2020 to Non Final Office Action dated Jul. 28, 2020”, 10 pgs. |
“U.S. Appl. No. 15/979,165, Supplemental Notice of Allowability dated Jan. 7, 2021”, 5 pgs. |
“U.S. Appl. No. 16/198,216, Non Final Office Action dated Aug. 6, 2020”, 15 pgs. |
“U.S. Appl. No. 16/198,216, Notice of Allowance dated Nov. 18, 2020”, 9 pgs. |
“U.S. Appl. No. 16/198,216, Notice of Allowance/Base Issue Fee dated Nov. 18, 2020”, 9 pgs. |
“U.S. Appl. No. 16/198,216, Response filed Nov. 5, 2020 to Non Final Office Action dated Aug. 6, 2020”, 13 pgs. |
“Australian Application Serial No. 2014340652, First Examination Report dated Dec. 13, 2018”, 2 pgs. |
“Australian Application Serial No. 2014340652, Response filed Nov. 12, 2019 to First Examination Report dated Dec. 13, 2018”, 69 pgs. |
“Canadian Application Serial No. 2927581, Office Action dated Jun. 9, 2020”, 4 pgs. |
“Canadian Application Serial No. 2927581, Office Action dated Oct. 10, 2019”, 4 pgs. |
“Canadian Application Serial No. 2927581, Office Action dated Dec. 8, 2020”, 3 pgs. |
“Canadian Application Serial No. 2927581, Response filed Jan. 18, 2021 to Office Action dated Dec. 8, 2020”, 18m pgs. |
“Canadian Application Serial No. 2927581, Response filed Apr. 9, 2020 to Office Action dated Oct. 10, 2019”, 8 pgs. |
“Canadian Application Serial No. 2927581, Response filed Oct. 7, 2020 to Office Action dated Jun. 9, 2020”, 17 pgs. |
“European Application Serial No. 14855587.3, Extended European Search Report dated Jun. 6, 2017”, 7 pgs. |
“European Application Serial No. 18881425.5, Extended European Search Report dated Dec. 7, 2020”, 6 pgs. |
“International Application Serial No. PCT/US2014/051235, International Preliminary Report on Patentability dated May 6, 2016”, 9 pgs. |
“International Application Serial No. PCT/US2014/051235, International Search Report dated Feb. 19, 2015”, 5 pgs. |
“International Application Serial No. PCT/US2014/051235, Invitation to Pay Additional Fees dated Dec. 10, 2014”, 2 pgs. |
“International Application Serial No. PCT/US2014/051235, Written Opinion dated Feb. 19, 2015”, 7 pgs. |
“International Application Serial No. PCT/US2018/062272, International Preliminary Report on Patentability dated Jun. 4, 2020”, 7 pgs. |
“International Application Serial No. PCT/US2018/062272, International Search Report dated Feb. 26, 2019”, 2 pgs. |
“International Application Serial No. PCT/US2018/062272, Written Opinion dated Feb. 26, 2019”, 5 pgs. |
“Modern Speech Recognition Approaches with Case Studies”, InTech, Chapter 10 Cochlear Implant Stimulation Rates and Speech Perception, (Nov. 28, 2012), 41 pgs. |
“Peripheral Nerve Stimulation: Percutaneous Lead Implantation Guide for Treatment of Chronic Pain”, Medtronic, Inc., (Jan. 1, 1999). |
Bulger, Robert, et al., “Combined Supraorbital (SONS) and Occipital Nerve Stimulation (ONS) for Intractable Post-Herpetic Neuralgia”, Neurology, 82, P7, (2014), 317. |
Dodick, D, et al., “Chronic Migraine Study Investigators; Evidence for Long-Term Efficacy of Peripheral Nerve Stimulation of the Occipital Nerves in the Management of Chronic Migraine”, Cephalalgia, 33, (2013), 58. |
Dodick, D W, et al., “Occipital Nerve Stimulation for Chronic Cluster Headache”, Advanced Studies in Medicine, 3, (Jan. 1, 2003), S569-S71. |
Dodick, David W, et al., “Safety and Efficacy of Peripheral Nerve Stimulation of the Occipital Nerves for the Management of Chronic Migraine: Long-Term Results from a Randomized, Multicenter, Double-Blinded, Controlled Study”, Cephalalgia, (2014), 15 pgs. |
Goadsby, P J, et al., “Current Practice and Future Directions in the Prevention and Acute Management of Migraine”, The Lancet Neurology, 9, (Jan. 1, 2010), 285-98. |
Linder, S L, “Combined Occipital Nerve/Supraorbital Nerve Stimulation for Treatment of Refractory Headaches: Initial Adolescent Experience (Ages 12 to 17)”, Cephalalgia, 31, (2011), 171. |
Lipton, R B, et al., “PRISM Study: Occipital Nerve Stimulation for Treatment-Refractory Migraine (p abs)”, Cephalalgia: an international journal of headache, 29: 30, (Jan. 1, 2009). |
Mueller, O M, et al., “Occipital nerve stimulation for the Treatment of chronic cluster headache—lessons learned from 18 months experience”, Central European neurosurgery. 72, (Jan. 1, 2011), 84-9. |
Redl, Richard, “Fundamental Considerations for Very High Frequency Power Conversion”, Electronic Feasibility Investigations, (Jan. 1, 2008), 24 pgs. |
Reed, K L, et al., “Combined Occipital and Supraorbital Neurostimulation for Chronic Migraine Headaches [abst]”, 15th Congress of the International Headache Society. Berlin, Germany: Cephalalgia, (Jan. 1, 2011), 98-9. |
Reed, K L, et al., “Combined occipital and supraorbital neurostimulation for chronic migraine headaches in adolescents (Ages 14-19): A retrospective analysis of 23 consecutive patients”, Cephalalgia. 33, (2013), 198. |
Reed, K L, et al., “Combined occipital and supraorbital neurostimulation for chronic migraine headaches: A multicenter retrospective analysis of 171 consecutive patients”, Cephalalgia, 33, (2013), 197-8. |
Reed, K, et al., “Combined Occipital and Supraorbital Neurostimulation for Chronic Migraine Headaches: An Extended Case Series (Abstract)”, Cephalalgia, 31, (2011), 98-9. |
Reed, K L, et al., “Combined Occipital and Supraorbital Neurostimulation for the Treatment of Chronic Migraine Headaches: Initial Experience”, Cephalalgia: an international journal of headache, 30, (Jan. 1, 2010), 260-71. |
Reed, K L, “Peripheral Neuromodulation and Headaches: History, Clinical Approach, and Considerations on Underlying Mechanisms”, Current Pain and Headache Reports, 17, (Jan. 1, 2012), 25-35. |
Reed, Ken L, “Concordant Occipital and Supraorbital Neurostimulation Therapy for Hemiplegic Migraine; Initial Experience; A Case Series”, Neuromodulation, (2015), 7 pgs. |
Reed, Ken L, “Peripheral Neuromodulation and Headaches: History, Clinical Approach, and Considerations on Underlying Mechanisms”, Current pain and headache reports, 17, (2013), 305-18. |
Reed, Kenneth, et al., “Combined concordant peripheral neurostimulation for chronic migraine headaches: A retrospective analysis of 188 consecutive patients (S41.001)”, Neurology, 82, (2014), 1 pg. |
Rooij, M, “eGaN FET based Wireless Energy Transfer Topology Performance Comparisons”, (Jan. 1, 2015), 5 pgs. |
Rooij, M, “eGaN FET based Wireless Energy Transfer Topology Performance Comparisons”, (Jan. 1, 2015), 6 pgs. |
Saper Jr., Dodick DW, et al., “Occipital Nerve Stimulation forthe Treatment of Intractable Chronic Migraine Headache: ONSTIM feasibility study”, Cephalalgia: an international Journal of headache, 31, (Jan. 1, 2011), 271-85. |
Schwedt, T J, “Occipital Nerve Stimulation for Chronic Headache-Long-Term Safety and Efficacy”, Cephalalgia: an international journal of headache, 27, (Jan. 1, 2007), 153-7. |
Silberstein, S, et al., “Efficacy of occipital nerve stimulatior for the management of intractable, chronic migraine: Results from a prospective, multicenter, double-blinded Controlled study”, Headache, 52, (2012), 866. |
Silberstein, S, et al., “Safety and Efficacy of Peripheral Nerve Stimulation of the Occiptial Nerves for the Management of Chronic Migraine”, Cephalalgia: an international journal of headache, (Jan. 1, 2012), 1-15. |
Silberstein, S, et al., “The Safety and Efficacy of Occipital Nerve Stimulation for the Management of Chronic Migraine”, Cephalalgia, 31, (2011), 117. |
Silberstein, Stephen D, et al., “Safety and Efficacy of Peripheral nerve Stimulation of the occipital Nerves forthe Management of Chronic Migraine: Results from a Randomized, Multicenter, Double-Blinded, Controlled Study”, Cephalagia, 32, (2012), 1165-79. |
Slavin, K V, et al., “Trigeminal and Occipital Peripheral Nerve Stimulation for Craniofacial Pain: A Single-Institution Experience and Review of the Literature”, Neurosurgical Focus, 21: E5, (Jan. 1, 2006), 5 pgs. |
Sreelakshmi, V, et al., “An RF-FC Converter with Wide Dynamic Range Input Matching for Power Recovery Applications”, International Journal of Advanced Research in Electrical, Electronics and Instrumentation Engineering, (Dec. 1, 2014), 14 pgs. |
Trentman, et al., “Greater Occipital Nerve Stimulation via the Bion Microstimulator: Implantation Technique and Stimulation parameters Clinical Trial: NCT00205894”, Pain Physician. 621-628, (May/Jun. 2009), 8 pgs. |
Weiner, Richard, et al., “Peripheral Neurostimulation to Control Intractable Occipital Neuralgia”, Neurosurgery, 45, (1999), 696. |
Weiner, Richard L, “Subcutaneous Neurostimulation for Intractable C2 Mediated Headaches”, Journal of Neurosurgery, 45, (2001), 2 pgs. |
Weiner, RL, et al., “Peripheral Neurostimulation for Control of Intractable Occipital Neuralgia”, Neuromodulation journal of the International Neuromodulation Society, 2, (Jan. 1, 1999), 217-21. |
U.S. Appl. No. 14/460,139, U.S. Pat. No. 9,042,991, Aug. 14, 2014, Implantable Head Mounted Neurostimulation System for Head Pain. |
U.S. Appl. No. 14/717,912, U.S. Pat. No. 9,974,968, May 20, 2015, Implantable Head Mounted Neurostimulation System for Head Pain. |
U.S. Appl. No. 15/979,165, U.S. Pat. No. 10,946,205, May 14, 2018, Implantable Head Mounted Neurostimulation System for Head Pain. |
U.S. Appl. No. 17/168,525, filed Feb. 5, 2021, Implantable Head Mounted Neurostimulation System for Head Pain. |
U.S. Appl. No. 14/879,943, U.S. Pat. No. 9,884,190, Oct. 9, 2015, Surgical Method for Implantable Head Mounted Neurostimulation System for Head Pain. |
U.S. Appl. No. 15/890,020, U.S. Pat. No. 10,850,112, Feb. 6, 2018, Surgical Method for Implantable Neurostimulation System for Pain. |
U.S. Appl. No. 17/085,434, filed Oct. 30, 2020, Surgical Method for Implantable Neurostimulation System for Pain. |
U.S. Appl. No. 14/989,674, U.S. Pat. No. 9,498,635, Jan. 6, 2016, Implantable Head Located Radiofrequency Coupled Neurostimulation System for Head Pain. |
U.S. Appl. No. 14/990,678, U.S. Pat. No. 9,539,432, Jan. 7, 2016, Implantable Head Located Radiofrequency Coupled Neurostimulation System for Head Pain. |
U.S. Appl. No. 15/402,090, U.S. Pat. No. 9,889,308, Jan. 9, 2017, Implantable Head Located Radiofrequency Coupled Neurostimulation System for Head Pain. |
U.S. Appl. No. 15/892,605, U.S. Pat. No. 10,695,571, Feb. 9, 2018, Implantable Head Located Radiofrequency Coupled Neurostimulation System for Head Pain. |
U.S. Appl. No. 14/990,654, U.S. Pat. No. 9,498,636, Jan. 7, 2016, Implantable Head Located Radiofrequency Coupled Neurostimulation System for Head Pain. |
U.S. Appl. No. 16/887,498, filed May 29, 2020, Implantable Head Located Radiofrequency Coupled Neurostimulation System for Head Pain. |
U.S. Appl. No. 15/599,206, U.S. Pat. No. 10,258,805, May 18, 2017, Surgical Method for Implatable Head Mounted Neurostimulation System for Head Pain. |
U.S. Appl. No. 16/198,216, filed Nov. 21, 2018, Low Profile Head-Located Neurostimulator and Method of Fabrication. |
“Australian Application Serial No. 2020201635, Response filed Sep. 23, 2021 to Subsequent Examiners Report dated Jun. 23, 2021”, 34 pgs. |
“U.S. Appl. No. 16/887,498, Non Final Office Action dated Oct. 28, 2021”, 26 pgs. |
“European Application Serial No. 14855587.3, Indication of deficiencies in a request under Rule 22 EPC dated Nov. 25, 2021”, 2 pgs. |
“U.S. Appl. No. 16/887,498, Response filed Jan. 27, 2022 to Non Final Office Action dated Oct. 28, 2021”, 12 pgs. |
“U.S. Appl. No. 17/085,434, Non Final Office Action dated Feb. 1, 2022”, 22 pgs. |
“U.S. Appl. No. 17/168,525, Non Final Office Action dated Sep. 29, 2022”, 21 pgs. |
“U.S. Appl. No. 17/168,525, Notice of Allowance dated Dec. 5, 2022”, 8 pgs. |
“U.S. Appl. No. 17/168,525, Response filed Sep. 13, 2022 to Non Final Office Action dated Apr. 28, 2022”, 11 pgs. |
“U.S. Appl. No. 17/168,525, Response filed Nov. 9, 2022 to Non Final Office Action dated Sep. 29, 2022”, 9 pgs. |
Number | Date | Country | |
---|---|---|---|
20210187304 A1 | Jun 2021 | US |
Number | Date | Country | |
---|---|---|---|
62589380 | Nov 2017 | US | |
61894795 | Oct 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16198216 | Nov 2018 | US |
Child | 17190544 | US | |
Parent | 14460139 | Aug 2014 | US |
Child | 14717912 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15599206 | May 2017 | US |
Child | 16198216 | US | |
Parent | 14879943 | Oct 2015 | US |
Child | 15599206 | US | |
Parent | 14717912 | May 2015 | US |
Child | 14879943 | US |